丰富环境和神经退行症之间的关系:从机制到治疗的审查
Yuan-Qiao Xu1,2,3, Yanjiao Chen4, Jia-Xin Xing5,6,7
1School of Forensic Medicine, China Medical University, Shenyang, People's Republic of China.
Clinical epigenetics
|January 24, 2025
概括
丰富的环境 (EE) 对神经退行性疾病 (NDs) 是有前途的. 通过调节关键分子通路和表观遗传过程,EE增强神经可塑性,减少炎症,并改善认知能力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 神经退行性疾病 (NDs) 是一个重大的全球健康挑战.
- 目前对ND的药理干预有局限性.
- 非药理学方法,如丰富环境 (EE),正受到越来越多的关注.
研究的目的:
- 审查EE对NDs相关的生物功能的影响.
- 探索EE神经保护作用背后的分子机制.
- 评估EE作为NDs补充疗法的潜力.
主要方法:
- 文献综述侧重于研究EE和ND的研究.
- 对动物模型 (动物和大型动物) 的分析.
- 检查分子通路,表观遗传修饰和自.
主要成果:
- EE增强神经可塑性,减少神经炎症,改善认知表现.
- EE调节关键的信号通路,包括ERK1/2,MAPK和AMPK/SIRT1.1,这些通路包括ERK1/2,MAPK和AMPK.
- EE影响表观遗传修饰和自,这些过程在ND病变发生过程中至关重要.
结论:
- EE是一种有前途的非药物干预措施,用于改善NDs.
- EE提供神经保护并增强认知功能.
- 经过EE可以作为一种有效的补充策略,与NDs的传统治疗一起使用.
相关概念视频
Alzheimer's Disease: Overview
439
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
439
Alzheimer's Disease: Treatment
160
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
160
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Parkinson's Disease: Overview
452
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
452
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95
Gene-Environment Interactions
248
Gene expression is a dynamic process that is significantly influenced by environmental factors. This interaction underlies the complex nature of biological development and the phenotypic differences observed among individuals, even among those with identical genetic makeups. Factors such as radiation, temperature, behavior, nutrition, and stress play pivotal roles in determining how genes are expressed. The concept of the reaction range is central to understanding this interaction. It posits...
248


